Auremolimab - Villaris Therapeutics
Alternative Names: INCA-034460; VM-6Latest Information Update: 10 Nov 2023
At a glance
- Originator Villaris Therapeutics
- Class Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 2 receptor beta subunit antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Vitiligo
- Research Autoimmune disorders